David A. Siegel Amylyx Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 470,000 shares of AMLX stock, worth $7.36 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
470,000
Previous 649,800
27.67%
Holding current value
$7.36 Million
Previous $2.3 Million
30.96%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding AMLX
# of Institutions
144Shares Held
75.8MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$138 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$124 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$93.1 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$71.1 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$70.5 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $917M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...